These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

472 related articles for article (PubMed ID: 30348224)

  • 21. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial.
    Kaufman HL; Russell J; Hamid O; Bhatia S; Terheyden P; D'Angelo SP; Shih KC; Lebbé C; Linette GP; Milella M; Brownell I; Lewis KD; Lorch JH; Chin K; Mahnke L; von Heydebreck A; Cuillerot JM; Nghiem P
    Lancet Oncol; 2016 Oct; 17(10):1374-1385. PubMed ID: 27592805
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100.
    Moehler M; Dvorkin M; Boku N; Özgüroğlu M; Ryu MH; Muntean AS; Lonardi S; Nechaeva M; Bragagnoli AC; Coşkun HS; Cubillo Gracian A; Takano T; Wong R; Safran H; Vaccaro GM; Wainberg ZA; Silver MR; Xiong H; Hong J; Taieb J; Bang YJ
    J Clin Oncol; 2021 Mar; 39(9):966-977. PubMed ID: 33197226
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.
    Rosenberg JE; Hoffman-Censits J; Powles T; van der Heijden MS; Balar AV; Necchi A; Dawson N; O'Donnell PH; Balmanoukian A; Loriot Y; Srinivas S; Retz MM; Grivas P; Joseph RW; Galsky MD; Fleming MT; Petrylak DP; Perez-Gracia JL; Burris HA; Castellano D; Canil C; Bellmunt J; Bajorin D; Nickles D; Bourgon R; Frampton GM; Cui N; Mariathasan S; Abidoye O; Fine GD; Dreicer R
    Lancet; 2016 May; 387(10031):1909-20. PubMed ID: 26952546
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Avelumab Versus Docetaxel in Patients With Platinum-Treated Advanced NSCLC: 2-Year Follow-Up From the JAVELIN Lung 200 Phase 3 Trial.
    Park K; Özgüroğlu M; Vansteenkiste J; Spigel D; Yang JCH; Ishii H; Garassino M; de Marinis F; Szczesna A; Polychronis A; Uslu R; Krzakowski M; Lee JS; Calabrò L; Arén Frontera O; Xiong H; Bajars M; Ruisi M; Barlesi F
    J Thorac Oncol; 2021 Aug; 16(8):1369-1378. PubMed ID: 33845211
    [TBL] [Abstract][Full Text] [Related]  

  • 25. First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study.
    D'Angelo SP; Lebbé C; Mortier L; Brohl AS; Fazio N; Grob JJ; Prinzi N; Hanna GJ; Hassel JC; Kiecker F; Georges S; Ellers-Lenz B; Shah P; Güzel G; Nghiem P
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34301810
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial.
    Sharma P; Retz M; Siefker-Radtke A; Baron A; Necchi A; Bedke J; Plimack ER; Vaena D; Grimm MO; Bracarda S; Arranz JÁ; Pal S; Ohyama C; Saci A; Qu X; Lambert A; Krishnan S; Azrilevich A; Galsky MD
    Lancet Oncol; 2017 Mar; 18(3):312-322. PubMed ID: 28131785
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma.
    Habra MA; Stephen B; Campbell M; Hess K; Tapia C; Xu M; Rodon Ahnert J; Jimenez C; Lee JE; Perrier ND; Boraddus RR; Pant S; Subbiah V; Hong DS; Zarifa A; Fu S; Karp DD; Meric-Bernstam F; Naing A
    J Immunother Cancer; 2019 Sep; 7(1):253. PubMed ID: 31533818
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma.
    Rajan A; Heery CR; Thomas A; Mammen AL; Perry S; O'Sullivan Coyne G; Guha U; Berman A; Szabo E; Madan RA; Ballester LY; Pittaluga S; Donahue RN; Tsai YT; Lepone LM; Chin K; Ginty F; Sood A; Hewitt SM; Schlom J; Hassan R; Gulley JL
    J Immunother Cancer; 2019 Oct; 7(1):269. PubMed ID: 31639039
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Avelumab treatment in Italian patients with metastatic Merkel cell carcinoma: experience from an expanded access program.
    Grignani G; Chiarion Sileni V; Pinto C; Depenni R; Fazio N; Galli L; Giuffrida D; Carnaghi C; Ciliberto D; Corsi DC; Queirolo P; Benincasa E; Venturini F; Fazzi G; Costa N; Ascierto PA
    J Transl Med; 2021 Feb; 19(1):70. PubMed ID: 33588870
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study.
    Horn L; Gettinger SN; Gordon MS; Herbst RS; Gandhi L; Felip E; Sequist LV; Spigel DR; Antonia SJ; Balmanoukian A; Cassier PA; Liu B; Kowanetz M; O'Hear C; Fassò M; Grossman W; Sandler A; Soria JC
    Eur J Cancer; 2018 Sep; 101():201-209. PubMed ID: 30077125
    [TBL] [Abstract][Full Text] [Related]  

  • 31. First-line avelumab treatment in patients with metastatic Merkel cell carcinoma: 4-year follow-up from part B of the JAVELIN Merkel 200 study.
    D'Angelo SP; Lebbé C; Mortier L; Brohl AS; Fazio N; Grob JJ; Prinzi N; Hanna GJ; Hassel JC; Kiecker F; von Heydebreck A; Güzel G; Nghiem P
    ESMO Open; 2024 May; 9(5):103461. PubMed ID: 38744102
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Avelumab in relapsed/refractory classical Hodgkin lymphoma: phase 1b results from the JAVELIN Hodgkins trial.
    Herrera AF; Burton C; Radford J; Miall F; Townsend W; Santoro A; Zinzani PL; Lewis D; Fowst C; Brar S; Huang B; Thall A; Collins GP
    Blood Adv; 2021 Sep; 5(17):3387-3396. PubMed ID: 34477818
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Avelumab in Combination with Axitinib as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma: Results from the Phase 1b VEGF Liver 100 Trial.
    Kudo M; Motomura K; Wada Y; Inaba Y; Sakamoto Y; Kurosaki M; Umeyama Y; Kamei Y; Yoshimitsu J; Fujii Y; Aizawa M; Robbins PB; Furuse J
    Liver Cancer; 2021 Jun; 10(3):249-259. PubMed ID: 34239811
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Avelumab in unresectable/metastatic, progressive, grade 2-3 neuroendocrine neoplasms (NENs): Combined results from NET-001 and NET-002 trials.
    Chan DL; Rodriguez-Freixinos V; Doherty M; Wasson K; Iscoe N; Raskin W; Hallet J; Myrehaug S; Law C; Thawer A; Nguyen K; Singh S
    Eur J Cancer; 2022 Jul; 169():74-81. PubMed ID: 35504244
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Avelumab in patients with previously treated metastatic Merkel cell carcinoma (JAVELIN Merkel 200): updated overall survival data after >5 years of follow-up.
    D'Angelo SP; Bhatia S; Brohl AS; Hamid O; Mehnert JM; Terheyden P; Shih KC; Brownell I; Lebbé C; Lewis KD; Linette GP; Milella M; Xiong H; Guezel G; Nghiem PT
    ESMO Open; 2021 Dec; 6(6):100290. PubMed ID: 34715570
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody.
    Donahue RN; Lepone LM; Grenga I; Jochems C; Fantini M; Madan RA; Heery CR; Gulley JL; Schlom J
    J Immunother Cancer; 2017; 5():20. PubMed ID: 28239472
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I Trial of Combination Therapy With Avelumab and Cabozantinib in Patients With Newly Diagnosed Metastatic Clear Cell Renal Cell Carcinoma.
    Li H; Sahu KK; Brundage J; Benson M; Swami U; Boucher KM; Gupta S; Hawks J; Sirohi D; Agarwal N; Maughan BL
    Oncologist; 2023 Aug; 28(8):737-e693. PubMed ID: 36952231
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Avelumab: A Review in Metastatic Merkel Cell Carcinoma.
    Shirley M
    Target Oncol; 2018 Jun; 13(3):409-416. PubMed ID: 29799096
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer.
    Mehnert JM; Varga A; Brose MS; Aggarwal RR; Lin CC; Prawira A; de Braud F; Tamura K; Doi T; Piha-Paul SA; Gilbert J; Saraf S; Thanigaimani P; Cheng JD; Keam B
    BMC Cancer; 2019 Mar; 19(1):196. PubMed ID: 30832606
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and clinical activity of atezolizumab in head and neck cancer: results from a phase I trial.
    Colevas AD; Bahleda R; Braiteh F; Balmanoukian A; Brana I; Chau NG; Sarkar I; Molinero L; Grossman W; Kabbinavar F; Fassò M; O'Hear C; Powderly J
    Ann Oncol; 2018 Nov; 29(11):2247-2253. PubMed ID: 30219915
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.